Has Jacqueline Romero, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,026 in general payments to Jacqueline Romero, MD across 214 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jacqueline Romero, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jacqueline Romero, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jacqueline Romero, MD

Neurology with Special Qualifications in Child Neurology · Marlboro, NJNPI 1912356270

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 214 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by UCB, Inc. at 28.1% of the total. Among neurology with special qualifications in child neurology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,026in general payments, 2019–2025

Across 214 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

UCB, Inc.$1K
SK Life Science, Inc.$623
Neurelis, Inc.$523
Neuropace, Inc.$246
AbbVie$173
Aucta Pharmaceuticals, Inc.$142
plus $1K from 20 others

What the payments were for

Food & beverage$4,025100%
Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
UCB, Inc.	57	$1,132
SK Life Science, Inc.	30	$623
Neurelis, Inc.	33	$523
Neuropace, Inc.	3	$246
AbbVie	11	$173
Aucta Pharmaceuticals, Inc.	11	$142
Lilly USA, LLC	7	$119
Acadia Pharmaceuticals Inc	7	$118
Supernus Pharmaceuticals, Inc.	6	$102
Jazz Pharmaceuticals Inc.	6	$99
Livanova USA, Inc.	4	$99
Lundbeck LLC	5	$93
Teva Pharmaceuticals USA, Inc.	6	$82
Pfizer	4	$71
Biomarin Pharmaceutical Inc.	3	$71
Otter Pharmaceuticals, LLC	4	$70
Impel Pharmaceuticals Inc.	3	$48
Aquestive Therapeutics, Inc.	3	$44
Azurity Pharmaceuticals, Inc.	2	$31
Otsuka America Pharmaceutical, Inc.	2	$30
Immedica Pharma US, Inc.	2	$28
AstraZeneca	1	$20
Sumitomo Pharma America, Inc.	1	$19
Novocure Inc.	1	$16
Biocodex, Inc.	1	$14
Medtronic	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,026 in reported general payments places this provider in the 90th percentile of 69 neurology with special qualifications in child neurology providers in New Jersey.

See all neurology with special qualifications in child neurology providers in New Jersey →

Medicare billing

Part B allowed, 2024

$26,210

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lamotrigine ErLamotrigine	13	$2,462

Paid to pharmacies, not to this prescriber.

Other neurology with special qualifications in child neurology in Marlboro

Sohum TrivediMarlboro$4K
Juliann PaolicchiHackensack$80K
Trevor DesouzaMorristown$14K
Rao PasupuletiHamilton$11K
Aliza AlterLivingston$9K
Sara RubensteinHackensack$7K
Carlos LastraNew Brunswick$5K
Romana KulikovaGarwood$4K
Rajeshwari MahalinghamNew Brunswick$3K
Vikram BhiseNew Brunswick$3K

See the full list for New Jersey →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →